公开(公告)号：US20170100374A1

公开(公告)日：2017-04-13

申请号：US15288249

申请日：2016-10-07

Applicant: AbbVie S.à.r.l. ,  Galapagos NV

Inventor： Katja E. Conrath ,  Steven M. Rowe

IPC: A61K31/4155 ,  G01N33/68 ,  C12Q1/68 ,  A61K45/06 ,  A61K31/36

CPC classification number: A61K31/4155 ,  A61K31/36 ,  A61K31/44 ,  A61K38/00 ,  A61K45/06 ,  C12Q1/6883 ,  C12Q2600/156 ,  G01N33/6872 ,  G01N33/6893 ,  G01N2333/705 ,  G01N2800/382 ,  G01N2800/52 ,  A61K2300/00

Abstract: A combination therapy including a modulator of the function (potentiator) of cystic fibrosis transmembrane conductance regulator (CFTR) protein, and one or two modulator(s) of the cellular processing and/or localization molecule (correctors) is provided in a method for treating cystic fibrosis in a subject having a mutation located between the amino acid residues 1164-1480 of full length wild-type CFTR.